<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (16 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> without or with ringed sideroblasts, 2 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts, 2 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation) received <z:chebi fb="0" ids="6067">13-cis-retinoic acid</z:chebi> at a dosage of 50-100 mg/m2/day for a minimum of 4 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>Twelve patients obtained an increase of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels greater than 1 g/dl and 7 showed an associated increase of granulocyte count greater than 50% of baseline values </plain></SENT>
<SENT sid="2" pm="."><plain>No significant biochemical signs of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> or liver damage were noted </plain></SENT>
<SENT sid="3" pm="."><plain>A sustained response was noted only in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> without or with ringed sideroblasts and <z:mpath ids='MPATH_458'>normal</z:mpath> or hypercellular bone marrow </plain></SENT>
<SENT sid="4" pm="."><plain>Five patients are still on therapy from 23 to 82 weeks without transfusion requirement and <z:hpo ids='HP_0000001'>all</z:hpo> have shown an improvement in performance status </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that 13-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi> may only be clinically useful in selected patients since in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> with blast excess the drug does not seem to improve the course of the disease </plain></SENT>
</text></document>